Metraipolis › archive › dc_030a80529964
Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor Response — Europe PMC PMID:37958355
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/37958355
- DOI
- 10.3390/cancers15215181
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-06T10:20:51.465Z
- SHA-256 of the archived text
50563ef6d766148b938860da8a161f5f9164169b6ac50de3aa5c639b20ee5660- Stable URL of this page
https://metraipolis.com/documento/dc_030a80529964
How to cite
Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor Response — Europe PMC PMID:37958355 — Europe PMC (en), https://europepmc.org/article/MED/37958355 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_030a80529964 (Metraipolis archive dc_030a80529964, sha256 50563ef6d766148b938860da8a161f5f9164169b6ac50de3aa5c639b20ee5660)
BibTeX
@misc{dc030a80529964,
title = {Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor Response — Europe PMC PMID:37958355},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/37958355},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_030a80529964; sha256 50563ef6d766148b938860da8a161f5f9164169b6ac50de3aa5c639b20ee5660},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/37958355. Agents can read the archived copy with the MCP tool read_document.